• AMAG Pharmaceuticals Inc., of Lexington, Mass., reported total revenues for the third quarter of $17.7 million, falling short of analyst estimates of $20.4 million. Revenue included $16.2 million in net U.S. sales for iron deficiency product Feraheme (fermuoxytol), which increased over the second quarter of 2012 due to improved pricing dynamics.